Bibliografia
1. Beckman MG, Hooper WC, Critchley SE, et al. Venous thromboembolism: a public health concern. Am J Prev Med2010;38:S495-501. 10.1016/j.amepre.2009.12.017 [PubMed] [CrossRef] [Google Scholar]
2. White RH. The epidemiology of venous thromboembolism. Circulation 2003;107:I4-8. 10.1161/01.CIR.0000078468.11849.66 [PubMed] [CrossRef] [Google Scholar]
3. Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998;158:585-93. 10.1001/archinte.158.6.585 [PubMed] [CrossRef] [Google Scholar]
4. Kearon C. Natural history of venous thromboembolism. Circulation 2003;107:I22-30. 10.1161/01.CIR.0000078464.82671.78 [PubMed] [CrossRef] [Google Scholar]
5. Galanaud JP, Kahn SR. Postthrombotic syndrome: a 2014 update. Curr Opin Cardiol 2014;29:514-9. 10.1097/HCO.0000000000000103 [PubMed] [CrossRef] [Google Scholar]
6. Kahn SR, Shrier I, Julian JA, et al. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Ann Intern Med 2008;149:698-707. 10.7326/0003-4819-149-10-200811180-00004 [PubMed] [CrossRef] [Google Scholar]
7. Søgaard KK, Schmidt M, Pedersen L, et al. 30-year mortality after venous thromboembolism: a population-based cohort study.Circulation 2014;130:829-36. 10.1161/CIRCULATIONAHA.114.009107 [PubMed] [CrossRef] [Google Scholar]
8. Wessler S, Reimer SM, Sheps MC. Biologic assay of a thrombosis-inducing activity in human serum. J Appl Physiol1959;14:943-6. [PubMed] [Google Scholar]
9. Kumar DR, Hanlin E, Glurich I, et al. Virchow’s contribution to the understanding of thrombosis and cellular biology. Clin Med Res 2010;8:168-72. 10.3121/cmr.2009.866 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
10. Mammen EF. Pathogenesis of venous thrombosis. Chest 1992;102:640S-4S. 10.1378/chest.102.6_Supplement.640S [PubMed] [CrossRef] [Google Scholar]
11. 12. Sevitt S. The structure and growth of valve-pocket thrombi in femoral veins. J Clin Pathol 1974;27:517-28. 10.1136/jcp.27.7.517 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
12. 46. Streiff MB, Agnelli G, Connors JM, et al. Guidance for the treatment of deep vein thrombosis and pulmonary embolism. J Thromb Thrombolysis 2016;41:32-67. 10.1007/s11239-015-1317-0 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
13. 47. Hylek EM, Regan S, Henault LE, et al. Challenges to the effective use of unfractionated heparin in the hospitalized management of acute thrombosis. Arch Intern Med 2003;163:621-7. 10.1001/archinte.163.5.621 [PubMed] [CrossRef] [Google Scholar]
14. 48. Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e495S-530S. [PMC free article] [PubMed] [Google Scholar]
15. 49. Garcia DA, Baglin TP, Weitz JI, et al. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e24S-43S.[PMC free article] [PubMed] [Google Scholar]
16. 50. Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e152S-84S. [PMC free article] [PubMed] [Google Scholar]
17. 51. Segal JB, Bolger DT, Jenckes MW, et al. Outpatient therapy with low molecular weight heparin for the treatment of venous thromboembolism: a review of efficacy, safety, and costs. Am J Med 2003;115:298-308. 10.1016/S0002-9343(03)00326-7
18. Stevens SM, Woller SC, Baumann Kreuziger L, Bounameaux H, Doerschug K, Geersing GJ, et al. Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest. 2021 Jul 31:S0012-3692(21)01506-3. doi: 10.1016/j.chest.2021.07.055. Epub ahead of print. PMID: 34352278.
19. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e419S-94S.
20. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149(2):315-52.
21. Kearon C, Aki EA, Ornelas J, et al: CHEST Guideline and Expert Panel Report: Antithrombotic therapy for VTE disease. Chest 149:315–352, 2016. doi: https://doi.org/10.1016/j.chest.2015.11.022. Agnelli G, Becattini C, Meyer G, et al: Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 382:1599–1607, 2020. doi: 10.1056/NEJMoa191510
22. Raskob GE, van Es N, Verhamme P, et al: Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med Dec 12, 2017. doi: 10.1056/NEJMoa1711948
23. Young AM, Marshall A, Thirlwall J, et al: Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: Results of a randomized trial (SELECT-D).Clin Oncol 36: 2017–2023 ,2023, 2018.doim10.1200/JCO.2018.78.8034.
24. Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report j.chest.2021.07.055.Epub 11/Ott.2021
